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Background: Congenital heart defects (CHD), as the most common congenital anomaly, have been reported to
be frequently associated with pathogenic copy number variants (CNVs). Currently, patients with CHD are routinely
offered chromosomal microarray (CMA) testing, but the diagnostic yield of CMA on CHD patients has not been
extensively evaluated based on a large patient cohort. In this study, we retrospectively assessed the detected
CNVs in a total of 514 CHD cases (a 422-case clinical cohort from Boston Children's Hospital (BCH) and a 92-case
research cohort from Shanghai Children’s Medical Center (SCMC)) and conducted a genotype-phenotype analysis.
Furthermore, genes encompassed in pathogenic/likely pathogenic CNVs were prioritized by integrating several
tools and public data sources for novel CHD candidate gene identification.
Results: Based on the BCH cohort, the overall diagnostic yield of CMA testing for CHD patients was 12.8
(pathogenic CNVs)-18.5% (pathogenic and likely pathogenic CNVs). The diagnostic yield of CMA for syndromic
CHD was 14.1-20.6% (excluding aneuploidy cases), whereas the diagnostic yield for isolated CHD was 4.3-9.3%.
Four recurrent genomic loci (4q terminal region, 15q11.2, 16p12.2 and Yp11.2) were more significantly enriched
in cases than in controls. These regions are considered as novel CHD loci. We further identified 20 genes as the
most likely novel CHD candidate genes through gene prioritization analysis.
Conclusion: The high clinical diagnostic yield of CMA in this study provides supportive evidence for CMA as the
first-line genetic diagnostic tool for CHD patients. The CNVs detected in our study suggest a number of CHD
candidate genes that warrant further investigation.
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unless otherwise stated.[1,2]. The diagnostic yield of CMA testing ranges from
approximately 5% to 20% for patients with deve-
lopmental delay/intellectual disability (DD/ID), autism
spectrum disorder (ASD), or multiple congenital anom-
alies (MCAs), significantly higher than that of G-banded
karyotyping (3%) [3]. The American College of Medical
Genetics and Genomics (ACMG)recommends the use
of CMA as thefirst-tier diagnostic test for these pa-
tients [4].
Congenital heart defect (CHD) is among the most
common birth defects and is a leading cause of infant
mortality around the world. It affects approximatelyhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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that pathogenic CNVs are identified in a substantial
proportion of CHD patients [7,8]. Multiple recurrent
CNV loci such as 22q11.2 (the DiGeorge syndrome
region), 7q11.23, 8p23.1, 9q34.3, and 1q21.1 were found to
confer significant risk for syndromic or isolated CHD
[9-11]. These loci only explain a fraction of the genetic
underpinnings of CHD [7]. In recent years, CMA has
been routinely offered to patients with CHD. Several
studies have evaluated and reported the clinical diag-
nostic yields of such practice but largely based on small
patient cohorts [12-19]. Clinical diagnostic CMA data
have proven to be an invaluable source for genetic dis-
coveries and genotype-phenotype correlation studies.
Here, we retrospectively reviewed the CNV detection in
unselected clinical CHD cases at the Genetic Diagnostic
Laboratory of Boston Children's Hospital (BCH) and se-
lected research CHD cases from Shanghai Children’s
Medical Center (SCMC). We assessed the clinical signifi-
cance of each CNV and evaluated the overall diagnostic
yield. We further uncovered novel CHD-associated
CNVs and potential CHD candidate genes through gene
prioritization and pathway analysis.
Methods
Study subjects and phenotype classification
422 patients (56% male and 44% female, median age =
7 years) with at least one congenital heart defect who
underwent clinical CMA testing at BCH between
December 2006 and April 2013 were included in this
study. The relevant medical records, including clinical
notes and echocardiography reports, were reviewed. In
addition, 92 CHD patients (61 male and 31 female,
median age = 3 years) from SCMC were included in
this study. This group of patients was evaluated by
echocardiography, magnetic resonance imaging, cardiac
catheterization or surgical reports to determine the type
of CHD. SCMC patients with gross chromosomal aberra-
tions (e.g., trisomy 21 and trisomy 18) were excluded from
CMA analysis. Both studies were approved by respective
IRBs of Boston Children's Hospital and Shanghai Children’s
Medical Center. Informed consent for patients from SCMC
was obtained from parents. No identifiable information was
used in the manuscript. Cases ascertained at BCH included
all CHD phenotypes that were further subcategorized using
the classification system established by National Birth
Defects Prevention Study (NBDPS) [20], whereas cases
ascertained at SCMC primarily had conotruncal defects
(CTD). Patients who only had mild CHD abnormalities
(i.e. isolated patent ductus arteriosus and patent foramen
ovale) or were affected only by arrhythmia or cardiomyop-
athy were excluded from this study.
For comparison of CNV detection rate, a control cohort
was assembled from previously published studies [8,21,22],which used high-density microarray platforms comparable
to the ones used in this study.
Chromosomal Microarray testing and CNV evaluation
DNA samples from all cases were extracted from per-
ipheral blood with standard procedures. CHD patients
at BCH were tested on the Agilent 244 K comparative
genomic hybridization (CGH) array platform or a 4 × 180 K
SNP + CGH microarray in a clinical diagnostic setting.
CNVs were identified and evaluated as previously de-
scribed [23].
CHD cases at SCMC were tested on the Affymetrix
Cytoscan™ HD microarray platform in a research setting.
Data was visualized and analyzed by Chromosome Analysis
Suite (ChAS) software package (Affymetrix, USA) with a
minimal cutoff of 20 consecutive markers for CNV calling.
All CNVs reported are based on NCBI human genome
build 37 (hg 19).
Detected CNVs were evaluated through a filtering pro-
cedure and classified into five categories based on the
ACMG guideline [24] (for details see Additional file 1).
Statistical analysis
Two-sided Fisher’s exact test was used to compare the
frequencies of recurrent (n ≥ 3) CNVs between the case
and the control cohorts, the CNV detection rates between
isolated CHD and syndromic CHD, and the CNV burden
for each subcategory of CHD. A p value < 0.05 was consid-
ered significant throughout this study.
Gene prioritization for novel CHD candidate gene
identification
We developed an analytic process by integrating various
tools and data sources to prioritize the genes involved in
detected CNVs. RefSeq genes encompassed in the patho-
genic CNVs and likely pathogenic CNVs were assembled
as the starting gene list. The genes in deletions and dupli-
cations were analyzed separately (Additional file 1). Inde-
pendently, we also used the same prioritization process to
evaluate the novel CHD candidate genes involved in the
pathogenic CNV(s) of each patient.
Results
Diagnostic yield of CMA testing for patients with CHD
Among 422 CHD patients from BCH, 12 individuals were
found to have gross chromosomal aberrations including
five trisomy 21, five monosomy X, one trisomy 18, and
one 18q partial trisomy. In the remaining patients, we de-
tected 50 pathogenic CNVs in 42 patients (10.2%) and 28
likely pathogenic CNVs in 24 patients (5.8%) (Additional
file 1: Table S1, S2). The overall diagnostic yield of CMA
testing for patients with CHD was 18.5% when consider-
ing pathogenic, likely pathogenic CNVs and aneuploidies
as positive finding. The minimal diagnostic yield was
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ances (including aneuploidies) were included. The ma-
jority of pathogenic CNVs (~74%) detected in patients
were smaller than 10 Mb in size, which would presum-
ably be missed by karyotyping, again demonstrating the
superior technical validity of microarray in detecting
clinically relevant CNVs over karyotyping.
Diagnostic yield of CMA in syndromic vs. non-syndromic
CHD
All 12 patients carrying aneuploidy exhibited a syndromic
CHD phenotype. The remaining 410 individuals were di-
vided into two groups: isolated CHD or syndromic CHD
based on medical records. The former consisted of 162
patients and the latter consisted of 248 individuals exhibit-
ing extracardiac phenotypes in addition to heart defects.
The most common extracardiac phenotypes were ID/DD,
ASD, behavioral features, hypotonia and craniofacial dys-
morphism. Even after excluding aneuploidy cases, there
were significantly more non-polymorphic CNVs (CNVs
not recurrent in general population) in syndromic CHD
than in isolated CHD (Table 1, p = 0.0078). The p value
for pathogenic CNVs only (p = 0.0013) and for pathogenic
and likely pathogenic combined category (p = 0.0024) also
reached statistical significance. Based on this analysis,
the diagnostic yield of CMA for isolated CHD was
4.3% (pathogenic CNVs)-9.3% (pathogenic and likely
pathogenic CNVs), whereas the diagnostic yield for all
syndromic CHD (excluding aneuploidy cases) is 14.1
(pathogenic CNVs)-20.6% (pathogenic and likely patho-
genic CNVs) (Table 1).
Diagnostic yield of CMA related to CHD sub-types
We further compared the CNV detection rates between
syndromic CHD with co-occurring neurodevelopmental
disorders (NDD) including DD, ID and ASD with those
without NDD. Twice as many pathogenic CNVs were
detected in CHD patients with NDD than those without
NDD (Table 1), indicating that patients with co-morbid
features of CHD and NDD were more likely to harbor
pathogenic CNVs. This finding also suggested that CNVs
detected in syndromic CHD patients were not solelyTable 1 Association of CNV with isolated CHD and syndromic
CNV category Syndromic CHD cases
Syndromic CHD
cases with co-occurring
DD/ID or ASD (n = 75)
Syndromic CHD
cases without DD/ID
and ASD(n = 173)
Non-polymorphic CNVs 38 (50.7%) 60 (34.7%)
Pathogenic CNVs 17 (22.7%) 18 (10.4%)
Pathogenic + likely
pathogenic CNVs
22 (29.3%) 29 (16.7%)
aTwelve patients with aneuploidy were not included.
The following abbreviations were used: DD, development delay; ID, intellectual disacontributing to NDD which are known to be associated
with CNVs.
To further delineate the association of CHD sub-
categories with CMA detection rates, we classified the
BCH cases into nine categories (Additional file 1: Table S3).
Among patients with isolated CHD, those with compound
CTD (category F), hypoplastic left heart syndrome
(category G) and obstruction of left ventricular outflow
tract (category D) were more likely to harbor pathogenic
CNVs (Table 2). When all CHD cases were considered,
patients with isolated CTD (category E) exhibited the
highest CMA diagnostic rate (14.8%). In addition, CHD
patients with compound CTD (category F) and septal de-
fects (category A) also reached a >10% diagnostic rate. In
contrast, CHD patients with heterotaxy (category H) or
valve defects (categories C) were less likely to have a
pathogenic CNV.
Among 92 SCMC patients mainly affected with CTD,
a total of 26 non-polymorphic CNVs were detected, 11 of
them were classified as pathogenic or likely pathogenic
(Additional file 1: Table S1, S2). The CNV detection rate
for this cohort was about 12%, which is similar to that of
BCH patients with the same sub-phenotype, thus we inde-
pendently confirmed the significant involvement of CNV
in CTD.
Identification of known and novel recurrent CNVs
associated with CHD
A genome-wide CNV analysis for a total of 502 CHD
cases (410 from BCH cohort and 92 from SCMC cohort;
Additional file 1: Figure S1) led to the detection of 209
(183 in BCH cohort and 26 in SCMC cohort) non-
polymorphic CNVs. As a result, a total of 89 CNVs at 57
unique chromosome loci were considered to be of known
or possible clinical relevance in this study. They were
widely distributed on different chromosomes (Figure 1).
We observed 32 recurrent (n ≥ 3) CNVs distributed at six
chromosomal loci (Additional file 1: Table S1, S2) which
include 12 imbalances (nine deletions and three duplica-
tions) at 22q11.2 and five aberrations (three deletions and
two duplications) at the 8p23.1 involving the GATA4 gene,
both loci are known to be associated with syndromic orCHD
a Isolated CHD
cases (n = 162)
Syndromic CHD vs.
Isolated CHD p Valuep Value Total cases
(n = 248)
0.0234 98 (39.5%) 43 (26.5%) 0.0078
0.0163 35 (14.1%) 7 (4.3%) 0.0013
0.0275 51 (20.6%) 15 (9.3%) 0.0024
bility; ASD, autism spectrum disorder.
Table 2 Clinical relevance of CNV to CHD phenotypes
A C D E F G H
Isolated CHD cases
No. of cases n = 13 n = 19 n = 26 n = 8 n = 44 n = 31 -
Non-polymorphic CNV 4 (30.8%) 1 (5.3%) 7 (26.9%) 1(12.5%) 17 (38.6%) 7 (22.6%) -
Pathogenic CNV 0 0 1 (3.9%) 0 3 (6.8%) 2 (6.5%) -
Pathogenic + likely pathogenic CNV 0 0 4 (15.4%) 0 5 (11.4%) 3 (9.7%) -
All CHD cases
No. of cases n = 84 n = 41 n = 74 n = 27 n = 75 n = 47 n = 23
Non-polymorphic CNV 34(40.5%) 6(14.6%) 25(33.8%) 12(44.4%) 31(44.3%) 14(29.8%) 4(17.4%)
Pathogenic CNV 11(13.1%) 2 (4.9%) 6 (8.1%) 4 (14.8%) 10(13.3%) 3(6.4%) 1(4.4%)
Pathogenic + likely pathogenic CNV 17(20.2%) 2 (4.9%) 13(17.6%) 4 (14.8%) 13(17.3%) 5(10.6%) 3(13.0%)
The cases of B category was too low, thus not included. The twelve patients with aneuploidy were not included for calculation.
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with 4q terminal deletions which range from 4, 600 kb to
19, 300 kb in size (Figure 2A). Similar deletions were not
detected in 9170 control cases (Table 3), and are not re-
ported in DGV (http://dgv.tcag.ca/ accessed March, 2014).
4q terminal deletion is known to cause 4q- syndrome
where 50% of affected individuals have CHD, and a
cardiovascular critical region has been narrowed down to
4q32.2–q34.3 [25]. The smallest overlapping region (SOR)
among our 4q terminal deletion cases was about 4.6 Mb
in size at 4q35.1-qter. This SOR didn’t overlap with the
previously defined critical region (Figure 2A). Thus our
study potentially maps a novel CHD critical region at the
4q terminus. There were 24 Refseq genes at this interval,
although no known CHD genes existed, we propose
several possible candidate genes in discussion.Figure 1 Distribution of the 89 sub-chromosomal genomic imbalance
loci 22q11.21 and 8p23.1 were two known pathogenic CNV hotspots in CH
15q11.2, 16p12.1 and Yp11.2 as potential pathogenic hotspots.In addition, we identified three other genomic loci
with significantly higher frequencies in cases than in
controls. These three loci were 15q11.2 (p = 0.0289),
16p12.2 (p = 0.0025) and Yp11.2 (p < 0.0001) (Table 3)
respectively, which were also considered as possible
novel loci associated with cardiac development.
Identification of novel CHD candidate genes
Among 57 CNV regions of interest, ten CNVs contained
genes known to be causal for CHD (Additional file 1:
Figure S1 and Table S4). In order to identify novel CHD
candidate genes, we examined the genes within the
remaining 47 loci (Additional file 1: Table S5). Starting from
647 genes in deletion CNVs and 517 genes in duplication
CNVs (Additional file 1: Figure S2), we performed a gene
prioritization process using Endeavour and ToppGene. 18s detected in this study among patients with CHD. Chromosomal
D patients. This study also identified deletions at loci 4q terminal,
Figure 2 Recurrent deletions in the 4q terminal region. (A) The previously reported cardiovascular critical region (4q32.2-q34.3) are located
proximal to the smallest overlapping region (SOR) defined in this study. The two regions do not overlap. The asterisk indicates the de novo
variant. (B) Two additional cases with deletion overlap with the SOR. Cases 1 from Strehle, EM, et al. [30] and Case 2 from Maurin et al. [29]. All
three 4q terminal deletions involved the SORBS2 gene.
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Table S6 and Figure S2) in duplication CNVs in the
category of "Cardiovascular System Development and
Function" were identified as novel CHD candidate genes
through mouse embryonic expression pattern analysis and
Ingenuity Pathway Analysis (IPA) analysis (for details see
Additional file 1).
Furthermore, the same gene prioritization process was
performed for individual cases carrying pathogenic
CNVs of unknown CHD significance. A total of 39 genes
were identified in 19 cases (Additional file 1: Table S7).Table 3 Recurrent CHD-associated CNV loci
Locus (hg19) CNV Size range (kb) Cardiac Phenotypes
4qter Deletion 4559-19269 DORV, right dominant A
multiple VSDs, BAV, CoA
arch, TOF, PFO
15q11.2 Deletion 245-2703 D-TGA, VSD, ASD, PS, Co
ventricular dysfunction
16p12.2c Deletion 480 ASD, TAPVC, PDA
Yp11.2 Deletion 1300-3000 ASD, CoA, PFO
acontrol cases from Soemedi et al. [8] and Cooper et al. [21].
bcontrol cases from Repnikova et al. [22].
cThe chromosome coordinates for this deletion map to 16p12.1 in hg18, but map tOf note, 20 of these genes were also contained in the
global prioritization list (bold genes in Additional file 1:
Table S7). These shared genes are considered to be the
most likely dosage sensitive novel CHD candidate genes.
Discussion
Diagnostic yields of CMA testing
CMA has been recommended as the first-line test in the
initial postnatal genetic evaluation of individuals with
MCAs, DD/ID and ASD [4]. CHD is known to be fre-





V canal, hypoplastic LV,
, DILV, hypoplastic aortic
5/502 0/9170a <0.0001
A, PDA, AS, AR, left 4/502 19/9170 0.0289
3/502 3/9170 0.0025
3/502 12/32850b <0.0001
o 16p12.2 in hg19.
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testing. In contrast to previous publications (Table 4), the
present study documents the diagnostic yields for several
sub-categories of syndromic and non-syndromic CHD
using the largest cohort.
Previous clinical studies have demonstrated a higher
CNV diagnostic yield in syndromic CHD than that in
isolated CHD, but these studies were all done separately
for either syndromic CHD or isolated CHD by different
array platforms (Table 4). Using the largest cohort of
CHD from one clinical setting, we were able to assess
the CMA diagnostic yields for both syndromic and iso-
lated CHD patients by the same CMA platform. Our
study convincingly demonstrated a significantly higher
CNV detection rate in syndromic CHD (18.1%) than iso-
lated CHD (4.3%).
Importantly, our data also revealed that the CNV diag-
nostic yields differ among different CHD subcategories,
indicating different CHD sub-phenotypes may have dif-
ferent pathogenic mechanisms. The findings that iso-
lated CTD, compound CTD, and septal defects were
more likely to be associated with CNVs than heterotaxy
or valve defects provided practical guideline for referring
CHD patients for CMA testing. However, the number of
cases in each sub-category was still small in this study.
Research involving a larger sample size is warranted to
further delineate the correlation between CNV rate and
CHD sub-phenotypes.
In the clinical setting, the pathogenicity of a CNV is
assessed based on gene content, CNV size, and litera-
tures. In many instances, the causal relationship betweenTable 4 Summary of the diagnostic yields of CMA in clinical s
CHD from literatures
Study Platform
1 Thienpont B, et al. (2007) [12] 1 Mb BAC/PAC
2 Richards AA, et al. (2008) [13] Nimblegen 385 K C
3 Erdogan F, et al. (2008) [14] tiling path BAC ar
4 Breckpot J, et al. (2010) [15] 1 Mb BAC/PAC
5 Goldmuntz E, et al. (2011) [16] Affymetrix GeneChip 10
6 Breckpot J, et al. (2011) [17] Affymetrix 6.0 arr
7 Connor JA, et al. (2013) [18] Not specified
8 Syrmou A, et al. (2013) [19] Agilent 244 K CGH
Agilent 4 × 180 K SNP +
9 Our study Same as above
Diagnostic yield was defined as the number of patients with abnormal aberrations
pathogenic chromosomal imbalances were detected in about 16%-25% of cases. Bu
aMany CNVs included were not necessary pathogenic.
bTwelve patients with gross chromosomal aberrations were included.a particular CNV and a particular phenotype cannot be
easily established. It is likely that not all of the pathogenic
CNVs detected are directly causative of CHD. Thus, the
exact diagnostic yield of causal CNVs for CHD may be
less than the overall pathogenic CNV detection rate
(12.8%). We identified 19 CNVs with known CHD genes
(Additional file 1: Table S2). In addition, we also detected
12 aneuploidies that are known to be causally associated
with CHD phenotypes. Therefore, a total of 31 cases out
of 422 (7.3%) have chromosomal imbalances that are
known to cause CHD. Additionally, we believe that a
significant fraction of the remaining CNVs currently with
unproven causal relationship with CHD may turn out to
be novel CHD loci (such as 4q terminal deletion and other
novel candidate CHD loci).Thus, although the exact diag-
nostic yield of causative CNVs is difficult to assess, it is
reasonable to believe that the actual diagnostic yields is
higher than 7.3%, and somewhat smaller than 12.8%. This
level of diagnostic yield is similar to that for ASD (7%)
[26], DD/ID or MCAs (10-12%) [3,27]. Thus our findings
provide strong evidence for CMA to be used as the first-
line genetic diagnostic test for patients with CHD as well.
Many CHD patients in our study exhibited comorbid
features of DD, MCAs or ASD, which are known to have
a significant association with CNV. The fact that syndromic
CHD patients have a higher pathogenic CNV detection rate
than cases with only DD/ID/ASD suggests that not all
CNVs detected in our syndromic CHD patients can be
attributed to the DD/ID or ASD phenotype. Our data
demonstrated an additive effect on CNV burden when
these phenotypes co-occur with CHD. The fact thatetting with different microarray platforms in studies of
Patients Diagnostic
yield (%)No. Phenotype
60 Syndromic CHD 10(16.6%)
GH 20 Syndromic CHD 5 (25%)
20 Isolated CHD 0
ray 105 Isolated CHD 4(3.8%)
90 Syndromic CHD 16(17.8%)
0 K array 58 Syndromic CHD 12(20.7%)
ay 46 Isolated CHD 2 (4.3%)
121 Unselected CHD 9 (7%)
array 55 Syndromic CHD 29 (52.7%)a
CGH array
162 Isolated CHD 7 (4.3%)
260b Syndromic CHD 47 (18.1%)
divided by the total number of cases tested. In patients with syndromic CHD,
t the diagnostic yield of CMA in isolated CHD cohort was poorly studied.
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rate of 4.3% further supports the significant contribu-
tion of CNV to the pathogenesis of CHD.
High diagnostic yields provided strong supporting evi-
dence to justify the routine use of CMA test in clinical
evaluation of patients with CHD. While diagnostic yield
is important, we are also interested to assess the clinical
utility of CMA test for patients with CHD. A follow-up
study will be focusing on how the CMA test results im-
pact patient care and management.
Discovering novel CHD loci and candidate genes through
CNV detection
In this study, the top five most frequently detected
genomic imbalance events in CHD cases were 22q11.2
deletion/duplication, 8p23.1 deletion/duplication, tri-
somy 21, monosomy X and 4q terminal deletion. The
first four genomic imbalances are known to be causally
related to CHD. TBX1 and GATA4 are the known key
causative genes for CHD phenotypes for 22q11.2 and
8p23.1, respectively. The fact that all five 4q terminal
deletion cases were detected in CHD patients and none in
the control strongly supports the notion that 4q terminal
deletion is a novel CHD-causing locus.
4q terminal deletion is a subgroup of 4q- syndrome,
which has CHD in about 50% of the cases. Our five patients
presented different CHD phenotypes, including CTD,
hypoplastic left ventricle, septal defects and obstruction
of left ventricular outflow tract. Additionally, three of
them have comorbid features of extracardiac presenta-
tions (Additional file 1). A cardiovascular critical region
(4q32.2-q34.3) has been mapped for the 4q- syndrome,
and three genes (TLL1, HPGD, and HAND2) were pro-
posed to be the key genes responsible for the cardiovas-
cular phenotypes [25]. Interestingly, the SOR region of
our five 4q terminal deletion cases does not overlap with
this cardiovascular critical region (Figure 2A), suggesting
that our 4.6 Mb region represents a novel CHD critical
locus.
4q terminal deletions often co-occur with terminal
duplications of other chromosome as a consequence of
imbalanced segregation of a balanced parental trans-
location. In our study, the three largest 4q terminal
deletion cases also carried terminal duplications on an-
other chromosome (Additional file 1). The fact that the
other involved chromosomes were different in each
case and that the remaining two cases only carried the
pathogenic 4q terminal deletion makes a strong argu-
ment that it is the genes within the 4q terminal dele-
tion region, not on the other involved chromosomes,
that are causal for CHD phenotype. Through literature
review, we identified two other CHD cases with small
4q terminal deletions that overlapped with our SOR re-
gion (Figure 2B). All three 4q terminal deletions involvedthe SORBS2 gene, encoding a signal transducer that is
highly and nearly exclusively expressed in epithelia and
cardiac muscle tissue in the mouse embryo (Additional
file 1: Figure S3A). Strong expression in cardiac tissue
suggests that this gene may play a significant role in
heart development. Several previous studies also support
the SORBS2 gene as a critical gene for CHD [28-30].Our
SOR and case 2 (Figure 2B) also contained the PDLIM3
gene. The functional disruption of Pdlim3 in mice results
in right ventricular dysmorphogenesis, trabeculation
failure, and chamber dilatation [31,32], supporting the
involvement of this gene in heart development. Maurin
et al. suggested both PDLIM3 and SORBS2 were in-
volved in cardiac and muscle development, and could
be responsible for cardiac defects observed in terminal
4q35.1 deletions [29]. Additionally, the SLC25A4 gene
(MIM 103220), which encodes a member of the mito-
chondrial carrier subfamily of solute carrier protein,
was previously associated with familial hypertrophic
cardiomyopathy [33] and showed high expression in
mouse embryonic heart (Additional file 1: Figure S3B).
In fact, one case with 4q terminal deletion in our study
presented with cardiomyopathy. It is currently unknown if
any single gene at 4q terminal is sufficient to cause CHD,
or if CHD occurs due to multiple gene deletion. Based on
the above analysis, we propose that SORBS2, PDLIM3 and
SLC25A4 are the critical genes associated with 4q terminal
deletion for the CHD phenotype.
Recurrent deletions at locus 15q11.2 were statistically
enriched in our CHD cohort. The region between BP1
and BP2 at 15q11.2 has been previously implicated as a
contributory genetic cause of susceptibility to schizophre-
nia, behavioral disturbances, and intellectual disability
[34,35]. It is well known that the 15q11.2 deletion has low
penetrance (for example only 2% for schizophrenia) [36].
Soemedi et al. was the first one to report the strong as-
sociation of this variant with the risk of multiple heart
defects, especially left-sided malformations [8]. How-
ever, no additional study followed. Our study provides
independent support for the contributory role of 15q11.2
in CHD pathogenesis. We detected a total of 33 cases with
15q11.2 deletion. Three of them (9.1%) exhibited CHD
phenotypes. Thus the penetrance of 15q11.2 deletion for
CHD is also low. Additional genetic factors may be re-
quired for the manifestation of CHD.
We also identified three 16p12.1(hg 18) microdeletions
involving the EEF2K and CDR2 genes, which have been
previously linked to intellectual disability and neuro-
psychiatric phenotypes [37]. Other features including
cardiac anomalies are frequently observed in individuals
with 16p12.1 deletion. Girirajan et al. identified seven
individuals with CHD phenotype out of 21cases carrying
this imbalance [38], suggesting its significant predispos-
ing role to heart malformations. In our study, three out
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phenotype, demonstrating a relative high CHD penetrance
of this imbalance.
CNVs detected in CHD patients provide a unique
source for identifying novel CHD candidate genes. In
this study, using gene prioritization approaches, we
identified 20 novel candidate genes (11 genes in deletion
CNVs and nine genes in duplication CNVs, Additional
file 1: Table S9). We gathered additional supporting evi-
dence including gene expression and mouse phenotype
(Additional file 1: Table S9). We found that all of them
had positive expression in mouse embryonic or adult
heart. Some genes such as Ets1, Nfatc1, Cnn1 and Rps6ka2
exhibited a high expression level. The knock-out mice of
all genes in deletion CNVs (except Ptch1) exhibited abnor-
mal cardiovascular development. Of note, mice homozy-
gotes for the targeted null allele of Crk, Efnb2, Hey1,
Nfatc1 and Shh display defects in heart morphogenesis.
Although the function of these genes on human heart de-
velopment is still poorly studied, two heterozygous muta-
tions in NFATC1 were recently reported in a patient with
tricuspid atresia [39], and another recent study supported
that NFATC1 plays an important role in cardiac develop-
ment [40]. For genes in duplication CNVs, Dll1 knock-in
mice and mice with mutations of the Qki gene displayed
CHD involving impaired blood vessel morphology and ab-
normal heart looping. Taken together, these 20 genes are
considered to be the most likely candidate CHD genes.
Mutation screening in human CHD patients and func-
tional studies will provide further evidence to demonstrate
their causal relevance with CHD.Conclusion
In summary, the high clinical diagnostic yield of CMA for
patients with CHD justify CMA to be used as a first-tier
genetic test. Syndromic CHD cases are expected to have a
much higher pathogenic CNV detection rate. CMA also
provides diagnostic value for isolated CHD patients. The
CNVs detected in CHD patients represent a wealth of
CHD candidate genes that warrant further investigation.Additional file
Additional file 1: Supplementary data.Abbreviations
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